11-23 | MSF response to unprecedented decision to cancel funding round of the Global Fund to Fight AIDS, TB and Malaria, taken at board meeting in Accra, Ghana, November 21-22, 2011Because donor funding for global HIV/AIDS and the Global Fund has been declining, the Fund is in the most dire financial situation it has ever seen since its creation ten years ago. As a result, the Global Fund board on 22 November, decided to effectively cancel its 11th funding round due to lack of resources – an unprecedented act in its history.
11-21 | Latest UNAIDS treatment numbers show progress, but funding crunch is major threat
9-5 | Novartis will go before the Indian Supreme Court tomorrow in the latest attempt by the Swiss multinational pharmaceutical company to undermine a key public health safeguard in Indian patent law specifically designed to prevent drug companies from abusively patenting known medicines. If successful, the move would have a devastating impact on access to affordable medicines across the developing world, according to international humanitarian medical organisation Médecins Sans Frontières (MSF).
7-12 | Excluded countries should be ready to issue compulsory licences to access needed drugs An agreement announced today by pharmaceutical company Gilead to licence several HIV/AIDS drugs to the Medicines Patent Pool could improve access to medicines for patients, but excludes several countries with large numbers of people living with HIV, the international medical humanitarian organisation Médecins Sans Frontières (MSF) said today.
6-9 | Funds and affordable drugs needed to turn target into treatment On the heels of new evidence that shows HIV treatment is also HIV prevention, governments meeting at a UN Summit on AIDS have taken a critical step by committing to reach 15 million people with HIV treatment by 2015 – but they must take immediate concrete action to make this treatment target a reality, the international medical humanitarian organization Médecins Sans Frontières (MSF) said today.